Cardiac allograft vasculopathy (CAV) remains one of the main long-term complications after heart transplantation. We performed a systematic review focused on articles published in the previous 6 years to reappraise the novel evidences supporting risk factors, pathology, prevention, and treatment of CAV. We identified a search string for a literature search on PubMed. We excluded articles specifically focused on diagnosis/biomarkers/imaging only or complications of other diseases. We included 98 studies out of our search. Forty-eight articles describe risk factors for CAV, 13 pathology, 24 prevention, and 13 treatment for CAV. While confirming known concepts, we found supportive evidence that CAV pathophysiology may vary according to the time post-transplant and the prevalence of metabolic versus immune-mediated risk factors. Selective revascularization of focal lesions in patients with CAV may result in some clinical benefit, but CAV prevention, rather than treatment, by controlling risk factors and by using targeted immunosuppressive therapies is the most evidence-based approach to reduce disease progression.
Introduction
Although the survival after heart transplantation (HT) has improved considerably in the last decade [1, 2] , cardiac allograft vasculopathy (CAV) remains one of the main long-term complications, as a major cause of death and the most frequent cause of late graft dysfunction [3] . According to data from the Registry of the International Society for Heart Transplantation (ISHLT), within 10 years after HT about half of recipients develop CAV, and its detection more than doubles the risk of death the following year [1] .
Cardiac allograft vasculopathy is a rapidly progressive form of atherosclerosis, albeit characterized by a deceitful and silent development. Diffuse intimal hyperplastic lesions of the vascular tree, leading to vessel narrowing and eventually to allograft ischemia, represent CAV typical morphology, which makes standard coronary imaging tools insensitive [4] : its detection is uneasy and requires high-sensitive imaging and specifically developed classification criteria [5] .
Because of the cardiac denervation, patients with CAV mostly do not suffer from chest pain, which can be typical in native coronary artery disease [6] . Ventricular arrhythmias, congestive heart failure, or even sudden cardiac death may often be CAV 0 s first clinical manifestation [7] .
Cardiac allograft vasculopathy pathogenesis is characterized by a complex interplay between immunemediated and non-immune-mediated mechanisms [8] , rendering to a wide heterogeneity in vascular lesions, ranging from intimal thickening to complicated atheromas.
Therapeutic strategies for established CAV are limited. While interventions directed at reducing the impact of risk factors on CAV development showed some efficacy in pivotal studies [9, 10] , no specific drug therapy or revascularization strategy has evidence-based efficacy in limiting the clinical events in patients with CAV.
Altogether, this scenario still depicts CAV as an unavoidable destiny hanging over heart transplant recipients. Nevertheless, latest ISHLT registry data show a slight reduction in CAV incidence for patients transplanted in the most recent era [11] , suggesting that current post-transplant management may have indeed led to an improvement in CAV-related outcomes.
To substantiate the rationale for this hypothesis, and highlight the basis for further improvement in the near future, we performed a systematic review of the literature published in the latest 7 years (i.e., 2011-2017), aiming to shed light on current developments about CAV risk factors, pathology, prevention, or treatment of CAV.
Methods

Search strategy
To reduce as much as possible potential selection biases in the articles chosen to be included in this review, we applied the systematic review approach using Medical Subject Heading (MeSH) terms by searching PubMed on the 10th of October 2017. The following search protocol was used: Relevance of articles was screened by titles and abstracts. Full-text of all selected articles was then reviewed and categorized as reported in Results section.
Study selection and data extraction
We included studies focusing on risk factors, pathology, and prevention or treatment of CAV. Because we aimed at gaining new knowledge on potential novel therapeutic targets and on the effectiveness of interventions, we excluded from the systematic review articles specifically focused on diagnosis/biomarkers/imaging only, or complications of other diseases, although they might have been considered when supportive of findings of the included studies. Animal studies, case reports, and reviews were excluded as well. Finally, we excluded studies in which CAV has been reported as ancillary outcome and not specifically aimed at.
Titles and abstracts of the retrieved articles were independently reviewed by two reviewers (ML and KM). If there was any disagreement about the articles to include, it was resolved by both reading the full article and debating with the other authors on which criteria the study would be included or excluded.
After the studies were included, the following data were extracted from each study: year of publication, journal of publication, on which of our three subjects the study was, study type, study population, mean age of the study population, average follow-up time, type of risk factor/pathologic component/prevention/intervention studied, and main outcomes of the studies.
Results
PubMed search
Two hundred ninety-nine studies were retrieved out of the search on PubMed. After application of our inclusion and exclusion criteria, we selected 98 studies. The flowchart in Fig. 1 shows how the studies were included and excluded.
Of the included studies, 48 describe risk factors for CAV, 13 pathology, 24 prevention, and 13 treatment of CAV.
Risk factors for CAV
Of the 48 articles investigating risk factors for CAV, six had a prospective design [12] [13] [14] [15] [16] [17] , seven were subanalysis of multicenter registries [16, [18] [19] [20] [21] [22] [23] , and 36 were retrospective mostly single-center cohort studies (Table 1 ). In most of the studies, several factors emerged from the analysis as associated with CAV, but it has to be noted that only few were consistently reported in all studies, which analyzed widely variable sets of risk factors. Donor age, and antibody-mediated rejection (AMR) or donor-specific antibodies (DSA) are the most consistently analyzed and reported risk factor associated with CAV, emerging as major players in 17 (34%) and 12 (24%) of these articles, respectively. Among other factors potentially implicated in CAV development, the analyzed studies reported metabolic abnormalities (including elevated cholesterol or triglycerides, diabetes, and high body mass index), cigarette smoking, African ethnicity, pretransplant ischemic cardiomyopathy, donor-recipient, gender mismatch, and cytomegalovirus (CMV) infection. Toxoplasma serology, heart rate, retransplantation, and primary graft dysfunction were not associated with CAV, while heart-lung or heart-liver transplantation appeared to be protective.
Pathology of CAV
We found thirteen articles studying CAV in terms of pathological description. In this group, we included in vivo imaging studies focusing on specific morphological features of coronary lesions [60] [61] [62] [63] [64] [65] [66] , and on ex vivo or postmortem studies analyzing morphological and molecular phenotypes of CAV [67] [68] [69] [70] [71] [72] . Table 2 describes the main characteristics and outcomes of the retrieved papers. In addition to descriptive studies on plaque morphology and histopathological phenotype in CAV, the immune-mediated and inflammatory pathophysiology of CAV had been investigated by studies analyzing pathological AMR in CAV, monitoring of immune function and CAV, ectopic lymphoid structures, and neovascularization. The major novelties include findings supporting distinct pathways in CAV pathogenesis varying with the time from transplant, and strong evidence relating B-cell lineage -both as graftinfiltrating cells and as antibody-producing cells -in CAV development.
Prevention of CAV
Twenty-four studies investigated strategies for CAV prevention. The main study characteristics and outcomes are shown in Table 3 . Nine of these studies had a randomized controlled design, thus supporting strong evidence of the findings [73] [74] [75] [76] [77] [78] [79] [80] [81] . Most of studies (58%) investigated the effect of mTOR inhibitors (sirolimus or everolimus) in comparison with calcineurin inhibitors (CNIs, cyclosporin or tacrolimus) or to mycophenolate derivatives (MMF) [74, [76] [77] [78] [79] [80] [82] [83] [84] [85] [86] . The other agents investigated for CAV prevention included induction therapies, tacrolimus versus cyclosporine, Ace inhibitors, aspirin, statins and granulocyte-colony-stimulating factor [73, 75, 81, [87] [88] [89] [90] [91] [92] [93] .
Treatment of CAV
Thirteen of the included articles studied the treatment of CAV. In Table 4 , the main study characteristics and outcomes are shown. Percutaneous coronary intervention (PCI) was used in twelve studies [66, [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] . Four studies compared the use of bare metal stents (BMSs) with drug-eluting stents (DESs) [95, 96, 98, 103] . Coronary artery bypass grafting (CABG) was used in four studies [94, 97, 99, 104] . Three studies report about retransplantation as extreme treatment for CAV [94, 99, 105] . Of note, all were retrospective cohort HT, heart transplant, HTx, heart transplantation, sec, secondary measure, IVUS, intravascular ultrasound, AMR, antibody-mediated rejection, DSA, donor-specific antigen, ECMO, extracorporeal membrane oxygenation, re-HTx, heart retransplantation, HLTx, heart-lung transplantation, ICM, ischemic cardiomyopathy, SHLT, simultaneous heart-liver transplantation, TCMR, T-cell-mediated rejection, CAG, coronarography, DA, donor-transmitted atherosclerosis, CMV, cytomegalovirus, CAC, coronary artery calcium, LVSD, left ventricular systolic dysfunction, PCWP, pulmonary capillary wedge pressure. studies and three of them derived from multicenter large registries.
Discussion
In this paper, we performed a systematic review including original research articles dealing with risk factors, pathology, prevention, and treatment of CAV. Our aim was to summarize the evidences gained in the 2011-2017 period, and provide clinicians with up-to-date evidence, which could improve clinical practice in reducing the negative impact of CAV on post-transplant outcomes.
We selected eighty articles focusing on the four themes we identified per study design. Despite the fact that the vast majority of available "evidence" derives from single-center and retrospective studies, large registries overall confirm most of the findings of the smaller studies, in particular for the identification of CAV risk factors. The few prospective studies available, some of which multicenter and/or randomized, are focused on interventions for CAV prevention, while we regrettably were unable to find randomized studies supporting any strategy for CAV treatment: the only evidences available in this theme weakly stand on retrospective cohort studies. Regardless of the weakness of most studies, the consistency of some findings did provide a reasonable weight of evidence supporting meaningful advancement in the understanding of CAV.
Risk factors for CAV
The evidence from the analyzed studies supports a meaningful role in favoring CAV by donor age, DSA and AMR, metabolic abnormalities, donor/recipient gender mismatch, and, despite some controversies, CMV infection. Neutral effect was found for primary graft dysfunction, while combined heart-lung transplantation and heart-liver transplantation appear to be protective for CAV development.
Donor age, when analyzed, is consistently reported to be associated with CAV detection [12, 18, 20, 21, 23, 24, 28, 30, 33, [36] [37] [38] 43, 45, 50, 59 ]. This concept is not novel [106] and is mainly related to the risk of transmission of donor coronary lesions to the recipient, as also suggested by studies finding that male donors -more likely to bear subclinical coronary lesions -may be associated with CAV development [45] . The selected studies, however, do not clarify the old-times debate whether donor-derived lesions from older grafts are more likely to progress than de novo lesions from younger grafts [107] . In this regard is worth noting a study selected in the descriptive pathology section ( , on the other hand, showed that recipient age was significantly associated with increasing risk for CAV in children. Nevertheless, older recipients do bear a higher risk for overall poor outcome. In a study focused on late CAV progression, our group found an independent effect of age on the risk of fatal and nonfatal cardiovascular events, but not on the risk of imaging-detected progression of CAV [108] . Similarly, a large study from Tjang et al. [109] found that post-transplant outcome in older recipients (>55 years) is less favorable than in younger recipients (<55 years), with CAV being one of the main causes for late mortality. Altogether, these data can be interpreted by the concept that although recipient age may not be directly involved in the process of coronary lesions progression, older recipients bear more often multiple comorbidities and metabolic abnormalities that are related to increased risk of "standard" cardiovascular disease, and thus poor outcome. In support of this concept, older recipients with a low comorbidity profile show good outcomes after transplantation [37] .
Alloimmunity is the main drive of CAV development, as already noted by the pivotal study by Russel et al. [110] finding that CAV lesions are confined to the allograft, abruptly ending at the organ suture lines. More recently, DSA and manifestations of AMR have been extensively investigated as measurable markers of the immune activation against vascular alloantigens. In our review, we found that eleven of twelve studies supported DSA/AMR involvement with CAV development [17,25,34,39,44,47-49,51,56,58], with the only neutral study [14] likely underpowered by the very small sample size. Anti-HLA DSA class II and combination of class I and class II were found associated with angiographic CAV [47, 48] , while non-DSA HLA antibodies did not appear to bear meaningful risk [34] . These data reinforce results from older studies [111, 112] , and the parallel findings that pathology-defined AMR is associated with CAV [25, 44] . The specific impact of cellular rejection on CAV risk remains debated, with three small studies that found an association [38,50,62] and a large one that did not [45] . These discrepancies may be explained by the known low reproducibility of biopsybased diagnosis of cellular rejection or by the variable timings of CAV detection [8] . Altogether, available evidence clearly supports the concept that acute episodes of rejection may favor the onset of CAV, with DSA playing a pathogenic role by targeting HLAs expressed on the coronary endothelial layer [113, 114] .
A large bulk of debated evidences in the past supported a role for infections, in particular CMV, in CAV development [115] largely based on the findings that aggressive anti-CMV strategies appeared to reduce early CAV [116] . Recent studies, all based on retrospective cohort analyses, confirmed the uncertainties, providing suggestive, but weak, evidence supporting a role for CMV in CAV. In a large single-center retrospective cohort of patients receiving heterogeneous anti-CMV strategies, Johansson et al. [36] found that not only CMV disease but also subclinical infection reduced the CAV-free survival. In a current and homogeneously managed cohort of patients, Delgado et al.
[50] confirmed these findings by showing that CMV disease and subclinical high-titer viremia are independently associated with the development of CAV. On the other hand, Galli et al. [45] found that in multivariable analysis the association between CMV disease and increased in risk of CAV did not reach full statistical significance, while in children it was found that CMV serology had no association with development of CAV [117] .
Toxoplasma serology has also been investigated as potentially associated with CAV in two studies. However, both showed no impact of toxoplasma on CAV development [27,35], but one found that the D+/RÀ recipients showed a lower 5-year survival rate than the DÀ/RÀ group.
Metabolic abnormalities including diabetes, insulin resistance, and dyslipidemia are known and established risk factors for CAV development [118] . Extensive use of statins in clinical practice has made the impact of cholesterol on CAV development less detectable in recent studies, than it was in historical series. In addition, a subanalysis of a large randomized trial on everolimus revealed that the impact of cholesterol on CAV may be influenced by the immunosuppressive strategy: Only in mycophenolate arm, low-density lipoprotein (LDL) concentrations were proportionally associated with intimal thickness increase, despite everolimus patients showed more often hypercholesterolemia [80] . This finding suggests that everolimus-induced hyperlipidemia may not be harmful [119] and that in transplant recipients cholesterol concentration per se may no longer represent a reliable marker of lipid-induced injury to vessel wall. In this context, more sophisticated measurements of cholesterol activity have been recently proposed, such as cholesterol efflux capacity [42] , but the robustness of these findings and the clinical applicability still need to be confirmed [11] .
Markers of resistance to insulin, on the other hand, are consistently identified as associated with CAV development and likely identify an undertreated condition in current clinical practice. In particular, among the studies we retrieved, we found that overt diabetes [41], high fasting glucose and elevated body mass index [32] , and high concentration of triglycerides [108] -all markers of insulin resistance -are consistently associated with CAV development.
Kransdorf et al. accomplished a commendable result in integrating all these major risk factors associated with CAV in three prediction models derived from the ISHLT registry, developing a CAV risk calculator. In this paper, authors weighted the donor-and recipient-related factors at the moment of transplant in an algorithm allowing to predicting the risk of CAV 7 years after transplant. Of note, in these models, immunosuppressive therapy did not play any role in reducing CAV risk [20] .
Pathology of CAV
Availability of advanced imaging tools such as virtual histology intravascular ultrasound (VH-IVUS) and optical coherence tomography (OCT) allowed meaningful improvement in the in vivo descriptive pathology of CAV. Although it was not among our scopes to revise studies dealing with allograft coronary imaging per se, we included in our review those IVUS and OCT studies providing novel insights on the specific pathophysiological features of CAV.
Using VH-IVUS, Matsuo et al. [84] described the multilayer appearance of coronary plaque in CAV patients. Multilayer appearance was associated with increase in plaque volume, necrotic core volume, and dense calcium volume and was found to be a potential predictor of plaque progression. OCT imaging also revealed that coronary microchannels, which indicate intimal neovascularization, are a novel and relevant morphological marker of CAV progression [63] . OCT imaging also confirmed typical features of CAV [64] . When compared with native atherosclerosis, CAV lesions were more homogeneous along the coronary tree and presented more macrophage-rich lesions [64] . Using a combined approach with IVUS and OCT, Cassar et al.
[60] analyzed the time-dependent change of CAV lesions morphology. While uncomplicated "simple" intimal hyperplasia was a feature of early-stage CAV, longer after transplant authors describe increasing prevalence of complicated coronary lesions (i.e., thin fibrous cap, intimal laceration, thrombi) and of other plaque morphologies resembling the typical native atherosclerotic lesions of nontransplant patients. Similar findings have been reported in a postmortem study: Huibers et al.
[68] who described inflammatory lesions in patients dying in the first years after transplant and fibrous lesions with outward remodeling in patients long after transplant. In a more recent series, Stanford group found that early constrictive remodeling portend an adverse prognosis [61] . The relevance of the outward remodeling, on the other hand, has been highlighted by our group, finding that increase in vessel volume is associated with higher risk of cardiovascular events long term after transplant [108] .
Pathological correlates of the tight link between immune activation and CAV have been confirmed by several investigations. As already discussed, DSA and AMR are important risk factors for CAV, which can be viewed as the outcome of the chronic inflammatory injury mediated by non-complement-dependent mechanisms [114] , inflammatory cytokine release [120, 121] , suggesting that cardiac allograft recipients have a persistent immune activation long term after transplantation. Pathological evidence of this link has been shown by Loupy et al.
[70] who, analyzing postmortem heart allografts, found that pathology evidence of AMR was more often associated with specific phenotypes of coronary lesions, characterized by inflammation and myointimal hyperplasia, while it was not observed in patients with morphology of pure coronary atherosclerosis. Additional important observations supporting the role of allo-and autoimmunity in CAV development were consistently reported again by Huibers and by Chatterjee [69, 72] . With different methodologies and study design, both authors found perivascular B-cell lineage infiltrates in CAV allograft explants. Of note, these cells appeared to produce not only HLA-directed antibodies, but also non-HLA natural antibodies reactive to multiple autoantigens, consolidating the contribution of HLA-independent immunological mechanisms implicated in CAV development [72] , as already suggested by other several reports about anti-AT1r and anti-endothelial cell antibodies [122, 123] .
Prevention of CAV
Immunosuppressive treatments
The effect of induction therapy on CAV was analyzed by two observational studies. Use of antithymocyte globulins (ATG) [91] was associated with less IVUSdetected CAV in a study including 103 patients, 1 year after transplantation. Similarly, but in a study including just 13 patients [90] , basiliximab was as well found associated with less IVUS-defined CAV progression. In the past, other studies found that ATG is associated with less CAV progression, providing substantial evidence in support of this effect [124] . However, none of these studies, neither large registry data, demonstrated a survival advantage of ATG induction over no induction. Efficacy of Basiliximab in preventing CAV, on the other hand, has not been confirmed by other studies, and recent registry reports suggest that it may be associated with increased mortality in heart transplantation, when compared with ATG or no induction.
Several randomized and nonrandomized studies analyzed the impact of mTOR inhibitors (everolimus and sirolimus) on CAV progression (Table 3 ). There is overall compelling evidence that either associated with low-dose CNI [80, 83, 86] or as replacement for CNI [77, 82, 84] mTOR inhibitors are associated with lower progression of early signs of CAV, as assessed by IVUS. It should be underlined, however, that CAV prevention effect has been consistently reported only when these drugs are initiated during the first months after transplantation, while there is currently no evidence whether their initial efficacy is retained long term after transplant, or the effect on IVUS endpoint translates into a net clinical benefit. In this context, Guethoff et al. [85] report a long-term analysis of patients initially randomized to sirolimus and low-dose tacrolimus (TAC) or TAC plus MMF. After initial benefit in renal function, sirolimus strategy did not provide any advantage in CAV development, or overall survival, 8 years after transplant, in the intention-to-treat analysis. The low long-term tolerability of sirolimus may partially explain these findings, because more patients were discontinued sirolimus, than MMF, possibly contributing to the balancing of the outcomes. In addition, two studies, one of which randomized [78, 83] , found that late conversion to everolimus or sirolimus seems ineffective, possibly related to the difference in plaque composition at various stages of CAV development, while another small retrospective study supports opposite results with everolimus delaying late CAV progression [86] . Overall, these findings are in line with the reports discussed above about pathology and the CAV risk factors, supporting the model of two stages and morphologies CAV development: a first phase more related to immuno-inflammatory injury, characterized by concentric intimal hyperplasia, and a later phase in which the contribution of metabolic risk factors becomes more relevant, resulting in a different plaque and morphology composition, resembling that of native atherosclerosis.
While the superiority of TAC over cyclosporine (CsA) in biopsy-proven rejection is quite well established, differences in CAV development are controversial. In one single study, the use of TAC versus CsA in combination with MMF was analyzed in the setting of a follow-up analysis of a small, randomized, single-center, controlled trial [75] . Freedom from angiographic CAV was 45.8% in the TAC group vs. 8.0% in the CsA group (P = 0.003) after 10 years, with the combination CsA-MMF found as an independent risk factor for CAV development (OR: 3.6; CI: 1.1-11.4; P = 0.031). However, there was no statistical difference in long-term survival between the treatment groups. By contrast, S anchez-L azaro and Kobashigawa [125] found no significant differences in early IVUS-defined or late angiographic CAV [126] , again with no difference in long-term survival. In a small, randomized study, Klauss et al. [127] found greater progression of early IVUS-defined CAV in the TAC group compared to the CsA group (79% vs. 38%; P = 0.082).
Other drugs and therapeutic approaches
Statins are the cornerstone of prevention of native atherosclerosis, as well as CAV, following the pivotal randomized studies with pravastatin and simvastatin [9, 128] . More recently, a small but randomized study found that high-dose fluvastatin was associated with lower early CAV development [73] and an observational study in adult heart recipients found that statin use was associated with lower mortality [89] . When used in pediatric patients however, these drugs do not appear to be as effective [92] . Nevertheless, at least in adult patients, these novel findings, altogether with the previous literature, strongly support a benefit on clinical outcomes of statin therapy [129, 130] .
Ace inhibitors and aspirin are other two cornerstone drugs in prevention and treatment of native coronary artery disease, but, in contrast to statins, only recently their effect on CAV has been adequately reported. A recent multicenter, double-blind, randomized study found that ramipril does not slow development of epicardial plaque volume 1 year after transplant, but does stabilize levels of endothelial progenitor cells and improve microvascular function, two surrogate measures associated with long-term survival [81] . Early administration of aspirin, on the other hand, appears to provide a meaningful benefit on long-term CAV development and CAV-related clinical events, although by the weaker evidence of a retrospective propensity scorebased analysis [93] .
Potentially intriguing insights for CAV prevention derive from small studies, suggesting a role for granulocyte-colony-stimulating factor (G-CSF) and for highintensity interval training [87, 88] . In a nonrandomized study, G-CSF was initially used in patients with leukopenia because of the regulating role of G-CSF in hematopoiesis and innate immune response. In patients who received G-CSF therapy, the incidence of rejection or progressive CAV was significantly lower (8% vs. 53%) [131] . In a small, randomized study, physical activity program has been analyzed as a therapeutic approach. Patients allocated to high-intensity interval training developed less increase in plaque volume as assessed by IVUS. The initial benefits, however, were not retained in the long-term follow-up, when highintensity training was withdrawn [88, 132] .
Treatment of CAV
Treatment of established CAV is based on revascularization procedures and, at its extreme, on retransplantation. Numerous studies analyzed PCI and CABG: All of them are retrospective, and the angiographic efficacy has been only weakly translated in proven clinical benefits.
Percutaneous coronary intervention is the standard revascularization approach for CAV epicardial lesions. Patients with coronary lesions amenable to PCI or CABG had better prognosis than those with nontreatable lesions [97, 99] . Of note, the Prada-Delgado paper also suggests that patients with CAV not associated with ischemia had similar outcomes than patients with no CAV [97] . In-stent restenosis and target vessel revascularization appears to be less frequent in patients receiving DES than BMS, although the benefit in clinical outcome is controversial [95, 98, 133, 134] . Of note, instent restenosis identified patients at higher risk of subsequent death [94] .
Coronary Artery Bypass Grafting surgery is rarely performed because of the diffuse nature of CAV [135] and because of historical data on high perioperative mortality in these patients. However, recent studies reporting small case series show that in selected patients with multivessel symptomatic disease CABG perioperative mortality may to date be significantly reduced, despite long-term outcomes remain poor patients most likely to benefit from this approach are those with symptoms and multivessel coronary disease resembling native atherosclerosis [97, 99, 136, 137] . In this context, it is worth remembering the largest published series of HT recipients treated with CABG, although published out of the time frame of our interest, in which thirteen patients showed 83% survival after revascularization [136] .
Retransplantation is a controversial approach of treatment for CAV because of the organ shortage and increased perioperative mortality. Of note, in current era, retransplantation shows similar outcomes to primary transplant in selected age categories and when first-year conditioned survival is analyzed [16, [138] [139] [140] . A recent ISHLT registry analysis, however, found that patients retransplanted because of CAV show a similar outcome than patients with CAV treated with medical therapy, with a benefit suggested only for those with left ventricle dysfunction [105] .
Study limitations
This systematic review has been designed to cover updates on the novelties emerged in the latest years about CAV. Given the complexity of the disease, the large amount of literature involved, and the diversity of study designs and scopes, we chose to focus our work only on risk factors, pathological features, prevention, and treatment. Despite we used a systematic approach to minimize biases in study selection, it is possible that we have missed relevant papers not retrieved by our search string, or excluded because dealing mainly with imaging or biomarkers. In addition, because of the retrospective design of most of the studies, presenting variable and sometimes nonstandardized endpoints, it has not been possible to apply a meta-analysis approach to the study findings. Thus, the sum of the evidences we found should be regarded as qualitative and cannot be weighted by statistical methods.
Conclusions
Despite improvements in surgical and medical management yielded to significant benefit in heart transplant outcomes, CAV remain a significant threat to long-term survival. In this systematic review of recent literature, while confirming known concepts, we found supportive evidence that the CAV pathophysiology may vary according to the time after transplant and the prevalence of metabolic versus immune-mediated risk factors. B-cellmediated immunity appears to bear a growing importance and could represent a relevant therapeutic target for future interventional studies. 
